Addiction

Pacira Awarded New U.S. Patent Covering EXPAREL Composition

-- First in new family of EXPAREL patents -- -- Expands EXPAREL intellectual property and provides protection into 2044 -- PARSIPPANY,…

1 year ago

San Diego-Based Alcohol and Drug Rehab Facility Helps Patients Restore Dignity During the Addiction Recovery Process

SAN DIEGO, CA / ACCESSWIRE / December 2, 2024 / Many people don't realize that restoring one's dignity is an…

1 year ago

Unlocking the Mysteries of Consciousness: SIDHE Announces Revolutionary Research Pathways and Transformative Programs

Unlocking the Mysteries of Consciousness: SIDHE Institute Launches Groundbreaking Research and Transformative Programs Merging Ancient Wisdom with Modern Science to…

1 year ago

South Beach Detox Introduces Opioid Detox Program to Combat the Ongoing Opioid Crisis

To help combat the ongoing opioid crisis, South Beach Detox has introduced a new evidence-based opioid detox program that combines…

1 year ago

SPR® Therapeutics Debuts New SPRINT® PNS Data for Low Back, Shoulder, Knee, and Headache at the 23rd Annual ASRA Pain Medicine Meeting

Presentations include first reporting of data for the RESET™ Clinical Trial evaluating SPRINT PNS versus Standard Interventional Management for low…

1 year ago

BrainsWay Reports Promising Feasibility Data Showing Pain Reduction with Deep TMS Therapy

Reductions also seen in comorbid anxiety and depression symptomsBURLINGTON, Mass. and JERUSALEM, Israel, Nov. 20, 2024 (GLOBE NEWSWIRE) -- BrainsWay…

1 year ago

Psyence Biomedical Announces Favorable Result of Nasdaq Listing Qualifications Hearing

NEW YORK, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) (“Psyence Biomed” or the “Company”) today announced…

1 year ago

VitalHub announces SHREWD implementation with Winnipeg Regional Health Authority

TORONTO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Vitalhub Corp. (TSX: VHI) (OTCQX: VHIBF) (the “Company” or “VitalHub”) is pleased to…

1 year ago

Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at the American College of Rheumatology (ACR) Convergence 2024 Annual Meeting

Poster presentation highlighted results from confirmatory Phase 3 RESILIENT study of TNX-102 SL (sublingual cyclobenzaprine HCl) treatment demonstrating statistically significant…

1 year ago